T
Tianchen Biopharmaceuticals
An innovative drug research and development enterprise focusing on biological macromolecules
About Tianchen Biopharmaceuticals
Based in Shanghai, Tianchen Biopharmaceuticals (also known as Longbio Pharma) is a clinical-stage biopharmaceutical company established in 2018, concentrating on the research and development of innovative antibody and fusion protein drugs. The company was co-founded by Dr. Heng Liu and Dr. Bill Nai-chau Sun. Dr. Liu, the current CEO, previously served as the Director of Pre-clinical and CMC at Generon, where he was involved in the development of several innovative drugs. Dr. Sun is a serial entrepreneur who co-founded Tanox Inc. in 1986, which was later acquired by Genentech for $919 million. He was the main inventor of the first-generation anti-IgE antibody, Omalizumab (Xolair®), a blockbuster drug for asthma and allergic diseases.
The company's business model is centered on creating a pipeline of proprietary assets and then out-licensing them to larger biopharma partners who manage late-stage development and commercialization. Tianchen Biopharmaceuticals develops treatments for autoimmune disorders, allergies, and complement-mediated diseases, such as nephrology, dermatology, and ophthalmology. The company's revenue generation relies on licensing fees, milestone payments from partners, and potential future royalties on product sales. Since its inception, the firm has secured significant funding, raising a total of $41.5 million over five rounds, including a recent Series C round of $27.8 million in June 2025, with investors like Qiming Venture Partners and Honghui Fund.
Tianchen Biopharmaceuticals' lead product candidate is LP-003, a next-generation anti-IgE antibody for treating allergic diseases. LP-003 is designed to have a higher binding affinity and a longer half-life than existing treatments like Omalizumab, potentially allowing for less frequent dosing—from once every 2-4 weeks to once every 3-6 months. Currently in Phase III studies, LP-003 is being investigated for various indications, including allergic rhinitis, chronic spontaneous urticaria (CSU), and asthma. Another key pipeline asset is LP-005, a bifunctional complement inhibitor targeting both C3 and C5 for complement-mediated disorders. This candidate is in Phase II trials for conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and IgA Nephropathy (IgAN).
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Jun 2026 | $0 | — | Undisclosed | ↗ |
| SERIES B✓Equity / VC | May 2025 | — | — | Highlight Capital · Lingang Group | ↗ |
Growth signals
Latest recorded traffic for Tianchen Biopharmaceuticals is 1.4K monthly website visits, up 55.6% over the last three months. Tianchen Biopharmaceuticals's team grew 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tianchen Biopharmaceuticals in the Huangpu ecosystem
The Tianchen Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Everstone
Oriental Fortune Capital- HHHefei Hongda
- HYHuzhou Youcheng
- SIShanzheng Innovation
- CCChangshu Guofa Venture Capital
Qiming Venture Partners
Highlight Capital
Lingang Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tianchen Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tianchen Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








